By Fineline Cube 
Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series A financing round, raising USD 34 million. The funding was led by a private equity fund managed by Value Partners Group (HKG: 0806), one of Asia’s largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.
Funding and Future Plans
Proceeds from the Series A financing will be used to accelerate the research and development of advanced technologies for early disease screening. The company also plans to further improve the commercial layout of various cancer, women’s health, and infectious disease diagnosis solutions.
PHASE Scientific’s Technology and Products
PHASE Scientific boasts the patented PHASIFY urine concentration technology, which captures over ten times more biomarkers than current industry gold standards. This technology allows the company to develop a comprehensive suite of non-invasive tests for early detection of cancers, women’s health conditions, and infectious diseases. The company has launched more than 30 novel diagnostic products, covering areas such as respiratory tract, gastrointestinal tract, women’s health, sexual health, children’s health, and oncology.-Fineline Info & Tech